Belimumab, an anti-B lymphocyte stimulator (BLyS) monoclonal antibody, is approved for systemic lupus erythematosus; however, it is unclear if it can be used to treat specific skin lesions in this disease. In this analysis, we investigated the expression of BLyS and its receptors in skin lesions of different subtypes of cutaneous lupus erythematosus (CLE) using immunohistochemistry and gene expression analyses.
| BACKGROUND
Belimumab inhibits the survival of B-cell subsets by neutralizing the activity of B lymphocyte stimulator (BLyS, also known as B-cell activating factor, BAFF) and is the first of a new class of immunomodulators approved for systemic lupus erythematosus (SLE). This agent is used for active, autoantibody-positive SLE patients with high disease activity despite standard therapy. Elevated levels of BLyS and its receptors BAFF-R, BCMA and TACI have been observed in patients with SLE. [1, 2] Moreover, increased serum BLyS levels have also been detected in patients with other B-and T-cell-mediated diseases, such as alopecia areata, [3] rheumatoid arthritis [4] and with psoriasis. [5] It has further been observed that T cells infiltrating labial salivary glands from patients with Sjögren's syndrome express BLyS. [6] These results confirm that
BLyS plays an important role in B-and T-cell-mediated diseases. To our knowledge, however, no extensive data are available with regard to the expression of BLyS and its receptors in skin lesions of patients with cutaneous lupus erythematosus (CLE) and the inflammatory skin disorders atopic dermatitis (AD), psoriasis (Pso) and lichen planus (LP).
| Questions addressed
The aim of this study was to investigate the expression of BLyS and its receptors in CLE skin lesions
| EXPERIMENTAL DESIGN
The expression of BLyS and its receptors (BAFF-R, BCMA and TACI)
in skin lesions of patients with different subtypes of CLE, healthy controls (HC) and other inflammatory skin disorders (AD, Pso and LP) was analysed by immunohistochemistry. These data were confirmed by gene expression analyses, using an independent data set of CLE patients, published earlier by our group (GEO accession number: GSE95474). [7] Functional analyses of BLyS expression were performed with an established HaCaT-cell culture system using the immunostimulatory DNA-motif poly:dAdT as a CLE similar proinflammatory factor. [7] Further details on Experimental Design are provided in the Appendix S1.
| RESULTS
Expression of BLyS was seen in the epidermis (keratinocytes) and in the lymphocytic infiltrate in all investigated inflammatory skin disorders with the strongest expression in subacute cutaneous lupus erythematosus (SCLE), discoid lupus erythematosus (DLE) and LP (Table S1 ). In DLE, SCLE and LP (but not in AD, lupus erythematosus tumidus (LET) or Pso), a specific immunohistological pattern was seen in the epidermis: BLyS was particularly expressed by keratinocytes in the lower epidermal layer in areas with the strongest inflammatory infiltrate ("interface dermatitis") ( Figure 1A -E and Fig. S1 ). Functional analyses in cultured keratinocytes revealed a significant upregulation of BLyS expression after stimulation with immunostimulatory DNA motifs (poly:dAdT: Figure 1F ). Gene expression analyses in an independent data set of CLE patients confirmed an enhanced expression of BLyS in CLE subsets, when compared with healthy controls ( Figure 1G ).
All three BLyS receptors included in this study (BAFF-R, BCMA, TACI) were mainly expressed within the inflammatory infiltrate by lymphoid cells (Figs S2 and S3) and not found in cultured keratinocytes ( Figure 1F ). Compared to HC, the expression of BLyS and its receptors BAFF-R and BCMA was significantly higher in skin lesions of all CLE subtypes and in LP (Fig. S4 ). In comparison with HC, however, significant differences of TACI expression were observed only in SCLE and
LET, but not in DLE, AD, Pso and LP.
| CONCLUSIONS
The data of the present study demonstrate a strong expression of BLyS in the epidermis of different CLE subtypes, while its receptors (BAFF-R, BCMA and TACI) were expressed by lymphoid cells within the dermal infiltrate. Interestingly, we found BLyS expression particularly in the lower epidermis in skin areas with the CLE-typical "interface dermatitis." Our group recently showed that endogenous immunostimulatory DNA motifs can drive the lesional inflammation via the expression of IFN-regulated pro-inflammatory cytokines. [7] The present study complements these findings by adding BlyS to the network of DNAregulated pro-inflammatory factors, which are produced by keratinocytes and support the lesional inflammation in the skin of CLE patients.
To date, only a few studies focused on the expression of BLyS and its receptors in inflammatory skin disorders, [8] [9] [10] and our data are in accordance with the published results. In 2011, Chen et al [9] showed that the cellular origins of BAFF in healthy skin were keratinocytes and cells in dermis costained with anti-CD68 monoclonal antibodies. Moreover, immunostaining for BAFF-R and TACI expressions on skin sections and on cultured keratinocytes revealed that these two receptors were not expressed by keratinocytes, which is in accordance with the results of our analysis. In lesional skin of AD, keratinocytes, subpopulations of the infiltrating CD3+ T cells, and CD68+ macrophages also expressed BAFF, as shown by double-immunostaining on skin sections.
To our knowledge, the only analysis of BLyS and its receptors in CLE lesions were investigated by Chong et al [10] in 2014. In DLE skin lesions, BLyS and BAFF-R stainings were seen in inflammatory cells, such as CD3+ T cells and CD163+ macrophages, whereas the epidermis showed only high levels of BLyS, as have been demonstrated in our study. Moreover, significantly increased protein levels of BAFF-R in the skin of DLE patients compared to the levels in the skin of patients with Pso and HC were observed.
In conclusion, this study confirms the impact of BLyS and its receptors in the investigated subtypes of CLE. Importantly, our data identified BLyS as a pro-inflammatory factor, which is expressed mainly by lesional keratinocytes in inflamed skin areas at the dermo-epidermal junction. We further demonstrated that BLyS expression in keratinocytes is inducible by immunostimulatory DNAs. These DNAs are important pro-inflammatory factors which are released in the context of the CLE-typical "interface dermatitis" and drive the lesional inflammation. [7] Our findings further support the view that belimumab, an antiBLyS monoclonal antibody, might be a promising therapeutic option in patients with CLE. Prospective, randomized, controlled trials are 
